SARS-CoV-2 vaccination protects against infection-induced autoantibody formation 2302309
Rattachement africain : us, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Introduction SARS-CoV-2-CoV-2 infection is known to induce autoantibodies across a wide range of targets, including immune modulatory proteins and pro-thrombotic factors. It is not known if vaccination with SARS-CoV-2 mRNA vaccines would induce a similar autoantibody profile, or whether prior vaccination would protect recipients from autoantibody production upon SARS-CoV-2 infection. Methods Our group followed a cohort of over 65,000 blood donors across repeat donations in the COVID-19 era. We identified SARS-CoV-2 naïve donors who were infected without prior vaccination (n = 150) or were vaccinated then became infected (n = 100). We tested samples from the naïve time point and 6-10 weeks after infection (2 paired samples) or naïve then vaccination then infection (three samples) using a T7 bacteriophage array displaying 731,724 peptides (49 amino acids each) spanning the human proteome. Data were partitioned into five random groups and peptide comparisons between groups were performed using ranksum, with 80% used for training and 20% used for testing iteratively. Results Autoantibodies targeting 15 peptides were induced with a z-score >2 after SARS-CoV-2 infection of unvaccinated naïve donors (p < 1x10-5). Of these infection-induced autoantibodies, 1 was induced after mRNA vaccination, as well as 2 distinct vaccine induced autoantibodies. In donors who were infected after prior vaccination, autoantibody responses were blunted, targeting 7 of 15 peptides. Conclusion In contrast to SARS-CoV-2 infection of immunologically naïve individuals, SARS-CoV-2 mRNA vaccination induces only a limited autoantibody repertoire. Furthermore, prior vaccination protects against development of approximately half the autoantibodies induced by SARS-CoV-2 infection in this study. These data confirm the induction of autoantibodies following infection and underline both the safety of mRNA vaccines in terms of autoantibody induction, as well as potential protective effects of vaccination from COVID-19 associated autoimmunity. Funding Source NIH Topic Categories Viral Immunology (VIR)
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- SARS-CoV-2 vaccination protects against infection-induced autoantibody formation 2302309
- Date Crossref
- 28/07/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Vitalant pays non établi dans la noticeOrganisation à but non lucratif
-
Vitalant Research Institute pays non établi dans la noticeStructure de recherche
-
University of California pays non établi dans la noticeUniversité ou école supérieure
-
University of British Columbia pays non établi dans la noticeUniversité ou école supérieure
-
American Red Cross pays non établi dans la noticeOrganisation à but non lucratif
-
Westat (United States) pays non établi dans la noticeEntreprise
-
Chan Zuckerberg Initiative (United States) pays non établi dans la noticeEntreprise
-
Chan Zuckerberg Biohub pays non établi dans la noticeInstitution
Vitalant, Vitalant Research Institute et University of California, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.